Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis
NCT00554606
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
115
Enrollment
INDUSTRY
Sponsor class
Conditions
Rheumatoid Arthritis
Interventions
DRUG:
Canakinumab
Sponsor
Novartis